8-K: Compass Therapeutics Updates Oncology Pipeline and Clinical Data

Compass Therapeutics presented updated corporate information, including data from its COMPANION-002 clinical study for tovecimig, highlighting significant improvements in key endpoints.

Summary

• Compass Therapeutics, Inc. has released an updated corporate presentation detailing progress across its oncology pipeline.
• The presentation highlights data from the COMPANION-002 Phase 2/3 clinical study of tovecimig (CTX-009), a DLL4 x VEGF-A bispecific antibody, in patients with second-line (2L) Biliary Tract Cancer (BTC).
• Tovecimig, in combination with paclitaxel, demonstrated a statistically significant improvement in the primary endpoint of Overall Response Rate (ORR) at 18.0% compared to 5.3% for paclitaxel alone (p=0.0228).
• Key secondary endpoints also showed significant improvement, with median Progression-Free Survival (PFS) of 4.7 months for the combination versus 2.6 months for paclitaxel alone (HR=0.44, p<0.0001).
• Overall Survival (OS) data was confounded by a high crossover rate (54% of control patients received tovecimig), but post-hoc analyses showed improved OS in crossover patients treated with tovecimig.
• The company plans to meet with the FDA in Q3 2026 and submit a Biologics License Application (BLA) for tovecimig in BTC in late 2026, with potential approval in the second half of 2027.
• Compass Therapeutics also provided updates on its other pipeline candidates: CTX-8371 (PD-1 x PD-L1 bispecific antibody), CTX-10726 (PD-1 x VEGF-A bispecific antibody), and CTX-471 (CD137 agonist).
• Phase 1 data for CTX-8371 in post-checkpoint inhibitor patients showed promising responses in NSCLC, TNBC, and HL.
• CTX-10726 initiated Phase 1 studies in Q1 2026 with topline data expected in H2 2026.
• CTX-471 is advancing to a Phase 2 study in NCAM+ tumors, with a recommended Phase 2 dose identified.
• The company reported $195 million in cash and marketable securities as of Q1 2026, with a runway extending into 2028.
• Multiple clinical and regulatory milestones are anticipated through 2026 and 2027.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update, with strong clinical data for tovecimig meeting key endpoints and a clear regulatory path forward, alongside promising early data for other pipeline assets.

Positives

• Tovecimig demonstrated a statistically significant improvement in Overall Response Rate (ORR) in the COMPANION-002 study for 2L BTC (18.0% vs 5.3%, p=0.0228).
• Median Progression-Free Survival (PFS) was significantly improved with tovecimig plus paclitaxel (4.7 months vs 2.6 months, HR=0.44, p<0.0001).
• Post-hoc analysis showed improved Overall Survival (OS) in patients who crossed over to tovecimig treatment (12.8 months vs 6.1 months).
• The safety profile of tovecimig in combination with paclitaxel was generally consistent with prior studies, with no new safety signals identified.
• The company has a strong cash position of $195 million as of Q1 2026, providing a runway into 2028.
• Promising early data for CTX-8371 in post-checkpoint inhibitor settings (NSCLC, TNBC, HL) suggests potential in a difficult-to-treat patient population.
• CTX-471 has identified NCAM (CD56) as a potential predictive biomarker for patient selection.
• The company is well-positioned with multiple clinical and regulatory milestones expected in 2026 and 2027.

Negatives

• Overall Survival (OS) in the primary ITT analysis of COMPANION-002 was confounded by a high crossover rate, showing no significant difference (8.9 months vs 9.4 months, HR=1.05, p=0.78).
• While PFS2 post-crossover showed improvement (3.5 vs 1.9 months), the p-value was borderline (p=0.065).
• The safety profile of tovecimig plus paclitaxel showed increased rates of Grade 3 adverse events such as fatigue, hypertension, neutropenia, and diarrhea compared to paclitaxel alone.
• The company's development stage means it relies on future funding, and the success of its product candidates is subject to inherent uncertainties.
• The market for tovecimig in 2L BTC is substantial but competitive, with other therapies and potential new entrants.

Risks

• Compass Therapeutics' ability to raise additional funding needed to continue its business and product development plans.
• The inherent uncertainties associated with developing product candidates and operating as a development-stage company.
• The ability to develop, initiate, and complete clinical trials for, obtain approvals for, and commercialize any of its product candidates.
• Competition in the oncology therapeutics industry.
• Market conditions and regulatory hurdles for new drug approvals.
• The potential for unexpected safety or efficacy issues in ongoing or future clinical trials.
• Reliance on the success of specific clinical programs like tovecimig in BTC, CTX-8371 in post-CPI settings, and CTX-471 in NCAM+ tumors.

Future Outlook

Compass Therapeutics anticipates multiple clinical and regulatory milestones in 2026 and 2027, including an FDA meeting in Q3 2026, a BLA submission for tovecimig in late 2026, and potential approval in the second half of 2027. The company is also advancing its other pipeline candidates, CTX-8371, CTX-10726, and CTX-471, with data readouts and study initiations planned.

Management Comments

• The company is focused on bringing transformative oncology therapies to patients.
• Tovecimig has demonstrated compelling clinical activity in the post-checkpoint inhibitor setting, addressing a critical unmet need.
• The robust pipeline includes novel and diverse candidates with potential firstand best-in-class profiles.
• The company is building a focused commercial organization to support tovecimig and future launches.

Industry Context

StockSavvy.ai notes that Compass Therapeutics is operating in the highly competitive and rapidly evolving oncology drug development space. The company's focus on bispecific antibodies and novel mechanisms of action aligns with current industry trends aimed at overcoming resistance to existing therapies like checkpoint inhibitors and improving efficacy in difficult-to-treat cancers such as Biliary Tract Cancer.

Comparison to Industry Standards

• In the 2L Biliary Tract Cancer (BTC) setting, tovecimig plus paclitaxel achieved an ORR of 18.0%, which appears higher than historical benchmarks for other second-line treatments like FOLFOX (reported ORR of 5%).
• The median PFS of 4.7 months for tovecimig plus paclitaxel in the COMPANION-002 study is also notably longer than historical median PFS for FOLFOX in this setting (reported as 2.1 months).
• The OS analysis in COMPANION-002 was confounded by crossover, making direct comparison to industry standards challenging. However, the post-hoc analysis of crossover patients showed a median OS of 12.8 months with tovecimig, which is significantly higher than the 6.1 months median OS for patients who did not cross over and received paclitaxel alone.
• For CTX-8371, the observed responses in heavily pre-treated patients with NSCLC, TNBC, and HL post-checkpoint inhibitor therapy are encouraging, given the generally poor prognosis and limited treatment options in this population, where response rates to salvage therapies are often low.

Stakeholder Impact

• Shareholders: Positive impact expected from advancing key pipeline assets towards potential commercialization, with strong clinical data and a clear regulatory path for tovecimig.
• Patients: Potential for new, more effective treatment options for Biliary Tract Cancer and other advanced solid tumors.
• Healthcare Providers: Introduction of a novel therapy (tovecimig) for a significant unmet need in BTC, with supporting clinical data.
• Creditors/Lenders: The company's cash position and runway provide a degree of financial stability, reducing immediate concerns.

Next Steps

• Meet with the FDA to discuss COMPANION-002 data in advance of BLA submission.
• Submit Biologics License Application (BLA) for tovecimig in 2L BTC in late 2026.
• Initiate Phase 2 study for CTX-471 in NCAM+ tumors.
• Continue Phase 1 dose escalation and expansion for CTX-8371.
• Initiate Phase 1 study for CTX-10726.
• Prepare for potential tovecimig launch in 2H 2027.
• Continue building a focused commercial organization.

Key Dates

Recommendation

The filing presents strong positive data for tovecimig, meeting key endpoints and setting a clear path for regulatory submission. However, the OS data was confounded by crossover, and the company remains a development-stage entity reliant on future funding and successful commercialization. While promising, the inherent risks and the need for further de-risking events warrant a 'hold' recommendation pending BLA approval and market launch.

Keywords

Compass Therapeutics, Tovecimig, CTX-009, Biliary Tract Cancer, Oncology, Clinical Trials, COMPANION-002, DLL4 x VEGF-A, CTX-8371, PD-1 x PD-L1, CTX-10726, CTX-471, CD137, Biologics License Application, FDA, BLA Submission